Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Specific extracellular matrix remodeling signature of colon hepatic metastases.

Del Rio M, Mollevi C, Vezzio-Vie N, Bibeau F, Ychou M, Martineau P.

PLoS One. 2013 Sep 4;8(9):e74599. doi: 10.1371/journal.pone.0074599. eCollection 2013.

2.

Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.

Mazard T, Causse A, Simony J, Leconet W, Vezzio-Vie N, Torro A, Jarlier M, Evrard A, Del Rio M, Assenat E, Martineau P, Ychou M, Robert B, Gongora C.

Mol Cancer Ther. 2013 Oct;12(10):2121-34. doi: 10.1158/1535-7163.MCT-12-0966. Epub 2013 Aug 19.

3.

MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.

Paillas S, Causse A, Marzi L, de Medina P, Poirot M, Denis V, Vezzio-Vie N, Espert L, Arzouk H, Coquelle A, Martineau P, Del Rio M, Pattingre S, Gongora C.

Autophagy. 2012 Jul 1;8(7):1098-112. doi: 10.4161/auto.20268. Epub 2012 May 31.

4.

Selection for intrabody solubility in mammalian cells using GFP fusions.

Guglielmi L, Denis V, Vezzio-Vié N, Bec N, Dariavach P, Larroque C, Martineau P.

Protein Eng Des Sel. 2011 Dec;24(12):873-81. doi: 10.1093/protein/gzr049. Epub 2011 Oct 13.

5.

New Topoisomerase I mutations are associated with resistance to camptothecin.

Gongora C, Vezzio-Vie N, Tuduri S, Denis V, Causse A, Auzanneau C, Collod-Beroud G, Coquelle A, Pasero P, Pourquier P, Martineau P, Del Rio M.

Mol Cancer. 2011 May 27;10:64. doi: 10.1186/1476-4598-10-64.

6.

Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, Del Rio M, Gongora C.

Cancer Res. 2011 Feb 1;71(3):1041-9. doi: 10.1158/0008-5472.CAN-10-2726. Epub 2010 Dec 15.

Supplemental Content

Loading ...
Support Center